In clinical trials, CD40 agonists have demonstrated tolerable safety profiles, with some showing partial responses and disease stabilization in patients with pancreatic cancer, melanoma, and non-small cell lung cancer (NSCLC) (189–192). The gene discussed is CD40; the disease is non-small cell lung carcinoma.